Tuesday - July 1, 2025
Johnson & Johnson Leads With First PARP Inhibitor Combo to Improve Efficacy in Patients With HRR-Mutated MCSPC
June 04, 2025
RARITAN, New Jersey, June 4 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-mutated mCSPC

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsen . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products